Methodological Considerations in the Evaluation of Radiotherapy Technologies

Clinical Oncology

Volumn 24, Issue 10, 2012, Pages 707-709

  Burnet, N G ^a   Billingham, L J ^b   Chan, C S K ^c   Hall, E ^c   Macdougall, J ^c   Mackay, R I ^d   Maughan, T S ^e   Nutting, C M ^f   Staffurth, J N ^g   Illidge, T M ^h  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g CARDIFF UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; CLINICAL EVALUATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; EDITORIAL; HEART VALVE REPLACEMENT; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LONGEVITY; MEDICAL TECHNOLOGY; METHODOLOGY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTON RADIATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELATIVE BIOLOGIC EFFECTIVENESS; XEROSTOMIA;

CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; NEOPLASMS; PROGRAM EVALUATION; RADIOTHERAPY;

EID: 84868303977     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.06.003     Document Type: Editorial

References (17)

1. Barkun J.S., Aronson J.K., Feldman L.S., et al. Evaluation and stages of surgical innovations. Lancet 2009, 374(9695):1089-1096.
2. Mackay RI, Burnet NG, Green S, Illidge TM, Staffurth JN, on behalf of the NCRI CTRad Executive Group. Radiotherapy physics research in the UK: challenges and proposed solutions. Br J Radiol (in press).
3. Billingham L, Burnet NG, Macdougall J, et al. on behalf of the NCRI CTRad Executive Group. Approaches to the Evaluation of Rapidly Evolving Radiotherapy Technologies: Report from a Medical Research Council/CTRad Methodology Workshop 2010. Available at: http://www.ncri.org.uk/ctrad/documents/mrc_methodology_2010_workshop_report_for_web.pdf.
4. Dearnaley D.P., Khoo V.S., Norman A.R., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999, 353(9149):267-272.
5. Nutting C.M., Morden J.P., Harrington K.J., et al. PARSPORT Trial Management Group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011, 12(2):127-136.
6. Glasziou P., Chalmers I., Rawlins M., McCulloch P. When are randomised trials unnecessary? Picking signal from noise. Br Med J 2007, 334:349-351.
7. Dearnaley D.P., Sydes M.R., Graham J.D., et al. RT01 collaborators. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8(6):475-487.
8. Joffe S., Miller F.G. Equipoise: asking the right questions for clinical trial design. Nat Rev Clin Oncol 2012, 9(4):230-235.
9. Sheehan M, Timlin C, Peach K, et al. Position statement on ethics, equipoise and research on charged particle radiation therapy. Personal communication, based on the Workshop on Charged Particle Radiation Therapy Ethics, Wolfson College, Oxford, August 2011. http://www.ptcri.ox.ac.uk/CPTREthics/index.shtml.
10. Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 2008, 372(9656):2152-2161.
11. Sullivan R., Peppercorn J., Sikora K., et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011, 12(10):933-980.
12. Developing and evaluating complex interventions: new guidance 2009, Medical Research Council, Available at:, MRC, London. http://www.mrc.ac.uk/complexinterventionsguidance.
13. Bentzen S.M. Design of clinical trials in radiation oncology: saving lives not grays. Radiobiological modelling in radiation oncology 2007, 196-211. British Institute of Radiology, London. R. Dale, B. Jones (Eds.).
14. Coles C., Faivre-Finn C. Radiotherapy research trials in the UK: secrets of success. Clin Oncol (R Coll Radiol) 2012, 24(4):229-231.
15. Peters L.J., O'Sullivan B., Giralt J., et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 2010, 28(18):2996-3001.
16. Harrington K.J., Billingham L.J., Brunner T.B., et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer 2011, 105(5):628-639.
17. Normolle D., Lawrence T. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J Clin Oncol 2006, 24(27):4426-4433.